85 related articles for article (PubMed ID: 2445482)
21. Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
Bukowski RM; Legha S; Saiki J; Eyre HJ; O'Bryan R
Cancer Treat Rep; 1982 Aug; 66(8):1651-2. PubMed ID: 6286120
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.
Mittelman A; Ashikari R; Ahmed T; Savona S; Arnold P; Arlin Z
Cancer Chemother Pharmacol; 1988; 22(1):63-4. PubMed ID: 2456162
[TBL] [Abstract][Full Text] [Related]
23. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
Baker LH; Saiki JH; Jones SE; Hewlett JS; Brownlee RW; Stephens RL; Vaitkevicius VK
Cancer Treat Rep; 1977 Nov; 61(8):1595-7. PubMed ID: 200359
[No Abstract] [Full Text] [Related]
24. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Warrell RP; Berman E
J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.
Taylor SA; Crowley J; Vogel FS; Townsend JJ; Eyre HJ; Jaeckle KA; Hynes HE; Guy JT
Invest New Drugs; 1991 May; 9(2):195-7. PubMed ID: 1714887
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
Von Hoff DD; Green S; Surwit EA; Hannigan EV; Alberts DS
Am J Clin Oncol; 1990 Oct; 13(5):433-5. PubMed ID: 1699401
[TBL] [Abstract][Full Text] [Related]
27. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
Suto T; Yoshida Y; Sakata Y; Ono T; Yoshida T; Yamada N; Chida N; Oohira H
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1933-8. PubMed ID: 9797816
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
Von Hoff DD; Green S; Alberts DS; Stock-Novack DL; Surwit EA; Miller TP; Stephens RL
Am J Clin Oncol; 1991 Jun; 14(3):193-4. PubMed ID: 1709556
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Keating MJ; Kantarjian H; Talpaz M; Redman J; McCredie KB
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):461-6. PubMed ID: 2464794
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine therapy in macroglobulinemic lymphoma.
Kantarjian HM; Alexanian R; Koller CA; Kurzrock R; Keating MJ
Blood; 1990 May; 75(10):1928-31. PubMed ID: 1692487
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
32. From the Food and Drug Administration.
Nightingale SL
JAMA; 1990 Feb; 263(6):793. PubMed ID: 1688632
[No Abstract] [Full Text] [Related]
33. Phase II trial of amsacrine in patients with hepatoma: a Cancer and Leukemia Group B study.
Amrein PC; Richards F; Coleman M; Poulin RF; Holland JF; Weinberg V; Perry M
Cancer Treat Rep; 1984 Jun; 68(6):923-4. PubMed ID: 6329510
[No Abstract] [Full Text] [Related]
34. Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
Kish JA; Kopecky K; Samson MK; Von Hoff DD; Fletcher WS; Kempf RA; Muggia FM
Invest New Drugs; 1991 Feb; 9(1):105-8. PubMed ID: 1709151
[TBL] [Abstract][Full Text] [Related]
35. Responses of patients to arabinosyladenine-5'-phosphate correlated with an in vitro test.
Lepage GA; Khaliq A
Adv Enzyme Regul; 1978; 17():437-54. PubMed ID: 93404
[No Abstract] [Full Text] [Related]
36. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Boldt DH; Von Hoff DD; Kuhn JG; Hersh M
Cancer Res; 1984 Oct; 44(10):4661-6. PubMed ID: 6205751
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of epirubicin in hepatoma.
Shiu W; Mok SD; O SK; Tsao SY; Woo KS; Li A; Leung N; Martin C
Cancer Treat Rep; 1986 Aug; 70(8):1035-6. PubMed ID: 3015405
[No Abstract] [Full Text] [Related]
38. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial.
Ravry MJ; Omura GA; Bartolucci AA; Einhorn L; Kramer B; Davila E
Cancer Treat Rep; 1986 Feb; 70(2):311-2. PubMed ID: 3004729
[No Abstract] [Full Text] [Related]
39. [Virostatic therapy with adenine arabinoside].
Werner TG
Med Klin; 1978 Oct; 73(43):2. PubMed ID: 82198
[No Abstract] [Full Text] [Related]
40. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial.
Ravry MJ; Omura GA; Bartolucci AA
Cancer Treat Rep; 1984 Dec; 68(12):1517-8. PubMed ID: 6210143
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
